Short answer
Relay Therapeutics, Inc. (RLAY) filed its Q1 2026 10-Q quarterly report on May 5, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $3M (down 60.9% year over year) with net income of −$73M.
Q1 2026 key financials · XBRL
- Revenue
- $3M
- −60.9% YoY
- Net income
- −$73M
- +4.9% YoY
- Operating margin
- -2619.7%
- EPS (diluted)
- −$0.41
- +10.9% YoY
Source: XBRL data from the Relay Therapeutics, Inc. (RLAY) Q1 2026 10-Q on SEC EDGAR. USD.
Relay Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No explicit “no material changes” statement or quarter-specific newly added risk identified in the provided excerpt
- Clinical development risk: no completed large-scale pivotal trials, creating uncertainty around regulatory approval and commercialization
- Regulatory risk: FDA may require a companion diagnostic for RLY-2608 in a biomarker-defined population
- Operational risk: April 2026 Pfizer supply agreement remains subject to regulatory feedback for planned Phase 3 therapy combination
- Market risk: competing clinical trials may divert eligible patients and delay enrollment
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Relay Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.